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ABSTRACT: Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized in the 
brain by the formation of amyloid-beta (Aβ)-containing plaques and neurofibrillary tangles containing the 
microtubule-associated protein tau. Neuroinﬂammation is another feature of AD and astrocytes are 
receiving increasing attention as key contributors. Although some progress has been made, the molecular 
mechanisms underlying the pathophysiology of AD remain unclear. Interestingly, some of the main 
proteins involved in AD, including amyloid precursor protein (APP) and tau, have recently been shown to 
be SUMOylated. The post-translational modification by SUMO (small ubiquitin-like modifier) has been 
shown to regulate APP and tau and may modulate other proteins implicated in AD. Here we present an 
overview of recent studies suggesting that protein SUMOylation might be involved in the underlying 
pathogenic mechanisms of AD and discuss how this could be exploited for therapeutic intervention. 
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Alzheimer’s disease  
 
Alzheimer’s disease (AD) is recognised as the most 
common cause of chronic dementia among the aging 
population. It was estimated that 35.6 million people lived 
with dementia worldwide in 2010, with numbers expected 
to almost double every 20 years, to 65.7 million in 2030 
and 115.4 million in 2050 [1]. Increased incidence of AD 
occurs with increased life expectancy, and subsequently 
incurs an escalating economic and social burden. No 
effective treatment for AD exists; therefore, the 
understanding of the molecular mechanisms of cellular 
damage involved is a critically important area of research 
to find ways of tackling this highly debilitating condition.  
The onset of AD is characterised by a progressive decline 
in cognitive function whereby mild impairments in 
memory are surpassed by increasingly significant higher 
cognitive deficits in language, recognition and skilled 
movements [2]. Pathological studies have indicated that 
certain areas of the brain are predisposed to exhibiting 
senile plaques and neurofibrillary tangles, which, 
combined with the severe cognitive impairment, are 
hallmarks of AD [3]. The senile plaques are primarily 
comprised of aggregated amyloid beta (Aβ) peptide 
fragments and the neurofibrillary tangles are aggregates 
of a hyperphosphorylated form of the microtubule-
associated protein tau [4]. The combination of these 
features leads to severe synaptic dysfunction.  
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The exact molecular mechanisms involved in AD are 
still unknown. The synaptic loss and death of specific 
neuronal populations in AD are consequence of a cascade 
of multiple deleterious molecular and cellular events 
rather than a single pathogenic factor. Several lines of 
evidence support the hypothesis that accumulation of Aβ 
in the brain is the primary factor driving AD, whereas the 
formation of neurofibrillary tangles is proposed to result 
from an imbalance between Aβ production and clearance 
[5]. In addition to these classical neuropathological 
features, activation of glial cells has been documented in 
the AD brain, suggesting a contribution of 
neuroinflammation to the pathogenesis of AD [6, 7]. 
  
Aβ generation 
 
After synthesis in the endoplasmic reticulum, amyloid 
precursor protein (APP) is glycosylated, tyrosyl sulphated 
and sialyted in the Golgi complex [8]. The full-length 
protein has a relatively short half-life: both during and 
after its trafficking through the secretary pathway, it 
undergoes proteolytic cleavage to release its products into 
the vesicle lumen and extracellular space. It is not known 
when APP cleavage occurs, but evidence suggests that it 
is located near the cell surface [9].  
Three protagonist protein complexes have been 
identified as cleaving APP and its products: α-, β- and γ-
secretases. Enzymatic cleavage of APP by α-secretase 
occurs at the lysine 16-leucine 17 bond of APP, 
precluding the formation of Aβ. The resulting large 
amino-terminal fragment of APP is secreted from cultured 
cells and found in human cerebral spinal fluid, suggesting 
a constitutive presence. β-secretase activity combines the 
activities of two complimentary aspartyl proteases, β-site 
APP-cleaving enzyme (BACE)-1 and -2. β-secretase 
cleaves APP 16 residues n-terminal to the α-secretase 
cleavage site resulting in a smaller ectodomain and 
leaving a 99-residue stump in the membrane. The C-
terminal membrane fragments after α- or β-secretase 
cleavage can be further processed by a third enzyme, γ-
secretase. This is thought to be a tetramer complex located 
in the membrane, one component of which is the 
presinillin (PS)-1 protein, characteristic of the London 
Familial mutation. γ-secretase cuts in the middle of the 
transmembrane domain of APP [10].  
Following α-secretase cleavage, γ-secretase activity 
results in secretion of a 3 kDa fragment (p3), it has been 
observed in cerebral spinal fluid and plasma, suggesting 
that these cleavage pathways are happening constitutively 
and are not aberrant processes. Sequential cleavage of 
APP by β- and γ-secretases results in the production of the 
39-42 amino acid protein Aβ (amyloidogenic proteolytic 
pathwhay). The proportion of the 1-42 peptide appears to 
be increased in transgenic AD mice possessing a familial 
mutation which causes increased β-secretase cleavage, 
suggesting an imbalance of fragments [11]. 
 
Neurofibrillary Tangles and Tau 
 
Neurofibrillary tangles result from the intracellular 
accumulation of cytoskeletal elements and consist mainly 
of paired helical filaments, which are aggregates of the 
hyperphosphorylated form of the microtubule-associated 
protein tau [9]. The tangles disrupt the transport of cellular 
components, such as nerve growth factor, contributing to 
neurodegeneration. It is significant that tau accumulation 
has been related to cognitive impairment [12], suggesting 
that the disease process is sequential involving first the 
build up of toxic Aβ followed by that of tau, which leads 
to neurodegeneration. 
Plaques and tangles can occur independently of each 
other. For example, in Lewy body disease plaques of Aβ 
are seen with virtual absence of tau, and paired helical 
fragments of tau can be seen in less common 
neurodegenerative diseases such as Kuf’s disease and 
progressive supranuclear palsy [9]. This suggests that the 
mechanisms are functionally distinct, but are related in 
AD. 
 
Neuroinflammation in AD 
 
Neuroinﬂammation is commonly observed in various 
CNS conditions including neurodegenerative disorders 
such as AD [13]. The Aβ peptide triggers microglial and 
astrocytic gliosis, which plays several roles in the 
neurodegenerative process [14, 15]. Some of these roles 
include phagocytizing cell debris after synaptic rewiring 
and memory formation and the release of pro-
inflammatory chemokines and cytokines. These pro-
inflammatory cytokines can cause a vicious cycle of 
inflammation that has been characterized in a number of 
neurodegenerative diseases including AD [7, 16].  
Astrocytes are the most numerous cell-type in the human 
brain and are indispensable for maintaining a healthy 
CNS. They are receiving increasing attention as key 
contributors to neurodegenerative disease, including AD 
[17]. Loss of function in astrocytes, associated with 
astrocyte reactivity, is considered to have an important 
role in neurodegeneration [18]. In human patients, and 
mouse models of AD, there is increased astrocyte 
reactivity, assessed by up-regulation of the intermediate 
filament protein, glial fibrillary acidic protein (GFAP), 
and morphological changes in astrocytes [19, 20]. AD-
related Aβ peptides cause astrocyte reactivity and the 
expression of GFAP is strongly associated with AD 
disease severity and cognitive decline [21, 22]. 
Specifically, Aβ-treated reactive astrocytes have been 
shown to be involved in inflammatory responses and to 
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exacerbate neurotoxicity [23, 24, 25]. Astrocytes 
activated by Aβ produce chemokines and cytokines that 
may result in neuronal damage [26]. Receptor binding of 
chemokines and cytokines stimulates a variety of 
intracellular signaling pathways that have been implicated 
in AD, including the activation of protein kinase C (PKC), 
c-Jun N-terminal kinase (JNK), p38 mitogen-activated 
protein kinase (p38/MAPK), PI3 kinase (PI3-K), 
extracellular signaling-related kinase (ERK), as well as 
activation of caspase-1 and caspase-3 [27, 28].  
 
 
 
 
 
Figure 1. The SUMO conjugation pathway. SUMO is 
expressed as a precursor protein and processed by a SUMO 
protease (SENP). Mature SUMO is activated in an ATP-
dependent manner by the SUMO activating enzyme (E1) and is 
transferred through a transesterification process to the unique 
SUMO conjugating enzyme (E2) Ubc9. SUMO is next 
conjugated to the target lysine of a substrate (consensus 
sequence ΨKXE/D). Conjugation, in some instances, is 
facilitated by a SUMO E3 ligase. The sumoylation pathway is 
reversible as specific proteases can remove and recycle SUMO 
from modified substrates. 
 
 
 
 
Protein SUMOylation 
 
Protein SUMOylation is the covalent attachment of small 
ubiquitin-like modifier (SUMO) proteins to specific 
lysine residues in target proteins. This post-translational 
modification regulates many aspects of normal protein 
function, including interactions, subcellular localization, 
activity, stability and partnering, and it has been shown to 
modulate an increasing number of cellular pathways [29, 
30]. Three major SUMO isoforms, SUMO-1, SUMO-2 
and SUMO-3, are expressed in cells, with SUMO-2 and 
SUMO-3 being very similar to each other (96% identical 
in amino acid sequence), but different from SUMO-1. 
SUMO-4 has been described, but it is not yet clear 
whether it is endogenously expressed in cells. A gene for 
SUMO-4 has been described although the expression of 
SUMO-4 protein in cells is still controversial [31].  
 Like ubiquitin, SUMO isoforms are expressed as 
precursor proteins and need to be matured before they 
enter a multi-step enzymatic pathway that is comparable 
to but distinct from ubiquitination.  First, the SUMO 
protein is cleaved by one of the specific SUMO proteases 
called SENPs to expose the C-terminal diglycine motif 
required for conjugation to targets.  In an ATP-dependent 
reaction, the mature SUMO is covalently attached to a 
cysteine in the SUMO E1 activating enzyme. The SUMO 
is then transferred from the E1 to the SUMO E2 
conjugating enzyme, Ubc9, which attaches the SUMO to 
a lysine in the target protein that is typically, but not 
always found within the consensus sequence ψKX(E/D) 
(ψ represents a hydrophobic residue, K the lysine for 
SUMO conjugation, X any amino acid and E/D an acidic 
glutamate or aspartate residue). SUMO E3 ligating 
enzymes stimulate protein SUMOylation by associating 
with Ubc9 and substrates to increase the efficiency of the 
reaction (Figure 1) [31].  
 SUMOylation is a highly dynamic and reversible 
process as the same proteases involved in the maturation 
of the precursor proteins are also responsible for the 
removal and recycling of SUMOs from their substrates. In 
contrast to ubiquitin, which mainly tags proteins for 
degradation, SUMOylation is important for the normal 
functions of proteins in the cell. However, over the past 
few years, several studies have indicated that 
SUMOylation also has a role in aging and 
neurodegenerative diseases, including AD (Table 1) [32, 
33]. 
 Neurodegenerative diseases are characterized by an 
area-specific extensive neuronal loss: a recurring feature 
of these diseases appears to be aggregation and 
accumulation of misfolded proteins. A role of protein 
SUMOylation has been investigated in a number of 
neurodegenerative diseases, including brain ischemia and 
AD [33, 34], with variable effects on protagonist proteins 
involved in disease pathogenesis. Important proteins in 
the pathogenesis of AD, such as APP and tau are reported 
SUMO substrates [35]. 
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Table 1. The involvement of SUMOylation in Alzheimer’s disease, aging and neuroinflammation. 
 
Study (author and year) 
 
SUMO effect 
Li et al., 2003 [41] SUMO-3 overexpression reduces Aβ production via regulation of APP processing in 
HEK293 cells. Monosumoylation has a positive effect on Aβ production as opposed to 
polysumoylation, which negatively regulates Aβ production. 
Dorval and Fraser, 2006 [34] Inhibition of phosphatases by okadaic acid increased SUMO1-tau levels in HEK293 cells. 
Dorval et al., 2007 [42] SUMO-3 overexpression increases Aβ40/Aβ42 secretion and up-regulates the expression 
of BACE. Suppression of SUMO-1 or SUMO-2 does not affect APP levels or Aβ 
production in HEK293 cells. 
Takahashi et al., 2008 [44] SUMO-1 and phospho-tau colocalization is observed in degenerating neurites around 
neuritic amyloid plaques in the cortex of aged mice. 
Zhang and Sarge, 2008 [43] Sumoylation of lysines 587 and 595 of APP is associated with decreased levels of Aβ 
aggregates in HeLa cells. 
Ahn et al., 2009 [55] Genetic variations of Ubc9 gene might be associated with a risk of AD in the Korean 
population. 
Akar and Feinstein, 2009 [47] LPS decreases mRNA levels of SUMO-1, Ubc9 and SENP1 in primary astrocytes and a 
similar decrease occurred during normal aging in brain. 
Lee et al., 2009 [49] SUMOylation is required for the suppression of STAT1-dependent inflammatory 
responses by LXRs in IFN-γ-stimulated brain astrocytes. 
McMillan et al., 2011 [36] Changes in individual bands of SUMO-1 or SUMO-2/3 conjugation are apparent in the 
hippocampus, cortex and cerebellum, although global levels were unaltered in Tg2576 
mice (9 months). 
Fang et al., 2011 [56] BACE gene promoter activity is inhibited by the overexpression of SUMO proteins. 
Yang et al., 2012 [39] Free unconjugated SUMO-3 increases in the hippocampus may be correlated with 
spatial learning ability in old C57BL/6 mice.  
Yun et al., 2013 [38] SUMO-1 free protein is elevated compared to wild-type mice in APP/ PS1 double 
transgenic mice. SUMO-1 modulates Aβ generation via BACE1 accumulation. 
Hoppe et al., 2013 [48] SUMO-1 overexpression abrogates Aβ-induced increase in GFAP in primary astrocytes. 
Nisticò et al., 2013 [40] SUMO-1 conjugation is increased in Tg2576 mice in cortex and hippocampus (3 
and 6 months) and this is paralleled by increased expression levels of Ubc9 and SENP1 
in both brain regions. SUMO-2-ylation is decreased in old transgenic mice (17 months), 
concomitant with an elevated amyloid deposition, which occurs at this stage in AD mice 
model. 
 
Abbreviations: APP (Amyloid Precursor Protein), PS1 (Presenilin-1), HEK (Human Embryonic Kidney), STAT1 (Signal Transducers and 
Activators of Transcription-1), LXR (Liver X receptor), IFN-γ (Interferon-γ), Ubc9 (SUMO-conjugating enzyme), SENP1 (SUMO-specific 
protease 1), BACE (β-secretase 1). 
 
 
 
SUMOylation in AD 
 
Models to investigate the potential role of protein 
SUMOylation in AD include in vitro systems, such as 
primary neuronal and organotypic hippocampal slice 
cultures treated with Aβ and in vivo AD transgenic mouse 
models. While the first enable researchers to manipulate 
the SUMOylation pathway, by overexpression or 
knockdown of relevant proteins, the second provide a 
more physiological model that allows the observation of 
global levels of SUMOylation in different brain regions.  
Global SUMOylation in AD has been explored in 
different brain regions of an APP transgenic mouse model 
of AD. In this model, global levels of SUMO-1 or SUMO-
2/3 were not significantly altered between 9-month-old 
Tg2576 and wild-type mice. However, on examination of 
individual bands within these global SUMO blots, several 
SUMO-2/3 bands were considerably decreased in the 
Tg2576 mice compared to controls. This suggested that, 
at least at this disease stage, subtle changes in 
SUMOylation by SUMO-2/3 may occur [36]. In fitting 
with a role of SUMO-2/3 in Aβ-mediated cellular stress, 
an unbiased proteomic study of artificially generated 
amyloidogenic proteins pulled down SUMO-2 as an 
interacting protein amyloidogenic surface. Thus, SUMO-
2 may be down-regulated through its binding to amyloid 
proteins, such as Aβ and thus functionally impaired [37]. 
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 Recently, a study has been shown that over-
expression of the three SUMO isorforms (SUMO-1 to -3), 
in a neuroglioma cell line, up-regulated β-secretase 
(BACE-1) levels, and consequently resulted in altered 
APP processing and Aβ generation, independent of 
covalent SUMO conjugation. Moreover, SUMO-1 
depletion decreased BACE-1 and Aβ generation [38]. In 
the same study, an increase in free SUMO-1 levels, but 
not in SUMO-2/3 protein, was observed in 18-month-old 
APP double transgenic mouse compared to wild-type 
animals. SUMO-1 immunoreactivity increased in the 
brains of transgenic mice and was co-localized with 
amyloid plaques. In another study a significant increase in 
free unconjugated SUMO-2/3 levels was observed in the 
hippocampus of 25-month-old C57BL/6 mice compared 
to 7-month-old mice [39].  
More recently, another study performed an age-
related analysis on the expression levels of global protein 
SUMOylation and SUMO-related enzymes in the Tg2576 
mouse model of AD. Signiﬁcant differences in the 
SUMOylation/de-SUMOylation balance were observed at 
an early stage of the pathology. At 3 months, SUMO-1 
conjugation, but not SUMO-2/3 conjugation, was 
augmented both in cortical and hippocampal tissue of 
Tg2576 mice compared to wild-type mice. They also 
demonstrated that the increase of SUMOylation in 
Tg2576 brain corresponds to a high expression level of 
Ubc9 and SENP-1 at the same time point [40]. 
 Due to the conflicting results from these studies, it 
remains unclear and controversial how SUMOylation 
might be affected with aging and AD. Further studies are 
necessary to elucidate the contradictory and unresolved 
issues, including by which mechanisms SUMOylation 
regulates Aβ processing in neuronal cell types and in in 
vivo AD models. 
 
APP and SUMOylation 
 
Published interest in APP SUMOylation stems from an 
unbiased screen of a mammalian fetal cDNA library to 
explore potential modulators of APP metabolism. This 
identified full length SUMO-2, initially noted as SUMO-
3 and later corrected, as causing altered APP processing 
patterns. However, subsequent work produced 
inconclusive results: SUMO-2 increased both 
amyloidogenic and non-amyloidogenic processing of 
APP, but was not co-immunoprecipitated with APP, 
suggesting SUMO-2 did not bind APP directly. Effects 
were validated in human embryonic kidney 293 
(HEK293) cells and a human neuroblastoma cell line. In 
vivo work found subcellular restriction of SUMO-2 to the 
neuronal soma. Overall, no convincing role for SUMO-2 
was established, though findings were suggestive of a 
potential role in APP processing which merited further 
work [41]. 
Another study investigated overexpression and RNAi 
knockdown of SUMO-1, -2 and -3. Co-transfection of 
HEK293 cells with HA-tagged SUMO-1, 2 and 3 plus 
APP695 followed by examination of extracellular Aβ 
levels showed no SUMO-1 or -2 effects. However, 
overexpression of SUMO-3 increased Aβ40 and Aβ42 
levels, as well as the levels of APP. The observed APP 
degradation at a slower rate and the increase in BACE led 
to the idea of a SUMO-3-specific effect on BACE and 
APP. Using SUMO-3 conjugation and polymerization-
deficient mutants resulted in no differences in APP 
cleavage from the active, polymerizing form, suggesting 
that the effect is due to SUMO-3 monomers and is a non-
covalent effect or that some compensation is occurring. A 
decrease in SUMOylated substrates was observed after 
SUMO knockdown by RNAi, but no parallel changes in 
the amyloidogenic processing of APP were observed 
suggesting endogenous SUMO was not an essential 
regulatory factor and played an indirect role in APP 
processing and production of Aβ [42].  
In contrast with these observations, another study 
identified a ψKx(E/D) SUMOylation motif around lysines 
587 and 595 of APP. It is important to note that these 
lysines are adjacent to the β-secretase cleavage site of 
APP and lysine 595 is mutated in the APP found in the 
Swedish early-onset familial form of the disease. Using a 
His-tag pull-down of APP found it to be conjugated to 
SUMO-1 and -2, supporting the view that APP is 
SUMOylated. In addition, transfecting non-
SUMOylatable mutants at these lysines resulted in 
increased levels of Aβ. Mouse brain APP 
immunoprecipitation also indicated SUMO-1 and 
SUMO-2 conjugation. By up-regulating Ubc9, increased 
APP SUMOylation and decreased Aβ aggregates were 
observed. These data point towards the idea of a direct 
SUMOylation of APP to down-regulate the 
amyloidogenic pathway in AD [43]. 
These mixed results from different groups may be 
explained by different experimental approaches. Factors 
to consider are both covalent and non-covalent 
interactions of SUMO, compensatory factors of different 
SUMO proteins due to overexpression or knockdown of 
other SUMO proteins. In addition, the role of the 
proteasomal degradation pathway and interplay with 
ubiquitination may also have a compensatory role. None 
of the above studies look at direct effects in neuronal cells 
and are restricted mainly to heterologous expression 
systems. However, they imply a role of SUMOylation in 
APP processing by secretases, which merits further 
investigation. 
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Tau and SUMOylation 
 
Another obvious target for SUMOylation studies in AD is 
tau. Co-transfection of HEK 293 cells with His-tagged 
SUMO-1, -2 and -3 with tau showed conjugation of 
SUMO-1 to tau [34]. Potential SUMOylation sites were 
investigated and lysine 340 was one of the major acceptor 
sites identified. The correlation between phosphorylation 
states of tau was also investigated and SUMO was found 
to bind to dephosphorylated tau much more significantly 
than to phosphorylated tau, implicating a potential 
function of SUMO in binding to microtubule-bound tau 
(non-phosphorylated) to prevent its proteasomal 
degradation. Pharmacological decreases in 
phosphorylation or increases in microtubule stabilization 
up-regulated tau SUMOylation, suggesting preffered 
binding of SUMO-1 to soluble (mislocalised) tau. 
Pharmacological proteasomal inhibition significantly 
decreased tau SUMOylation and increased ubiquitination. 
Proteasomal inhibition is a common feature in aging and 
other neurodegenerative disorders and may implicate a 
mechanism of disruption of the SUMO pathway in tau 
tangle formation. 
SUMOylation was later investigated in in vivo 
models of AD. Immunohistochemical staining of APP, 
Aβ, phospho-tau and ubiquitin in cortical slices from 
Tg2576 mice revealed ubiquitin-APP co-localization 
occurred in neurites. However, few phospho-tau granules 
in the neuritic plaques were ubiquitin positive, whereas all 
phospho-tau granules and punctuate deposits were 
SUMO-1 positive. No SUMO-1 positive deposits were 
observed in non-transgenic mice [44]. Therefore, the 
results of this study correlate with Dorval and Fraser’s 
(2006) findings of proteasome failure and interplay of 
SUMO-1 and ubiquitin conjugation to tau in AD 
pathogenesis [34]. 
The above studies utilize either observational in vivo 
or in vitro cell line models for investigation of protein 
interactions in AD. Although they provide preliminary 
evidence for a role of SUMO proteins in AD pathogenesis 
involving APP and tau, validation in physiological 
systems such as neuronal cultures or organotypic slice 
cultures and further in vivo studies would increase the 
relevance of these results. In addition, although tau and 
APP are the most highly associated proteins with AD, and 
thus are obvious targets for investigation of 
SUMOylation, a plethora of proteins are implicated in AD 
and a more global approach could merit further 
investigation.  
 
SUMOylation and neuroinflammation  
 
Although several roles for SUMOylation in the brain have 
been reported, the involvement of SUMOylation in 
neuroinflammation is a relatively new topic and there are 
limited studies concerning glial SUMOylation. Growing 
evidence suggests that glial SUMOylation can impact 
cellular processes that are relevant under pathological 
conditions. SUMOylation can have pro- or anti-
inflammatory actions, depending on the specific SUMO 
isoform that is conjugated, the target protein and cell-type 
[45, 46].  
There is little data on SUMOylation in astrocytes. The 
first report confirmed the existence and functionality of 
this important signaling pathway in primary astrocytes 
showing that the mRNA levels for SUMO-1, the 
conjugating Ubc9 and the de-conjugating SENP-1 are 
decreased following treatment of astrocytes with 
lipopolysaccharide (LPS). This study suggested that loss 
of the SUMO pathway in astrocytes under inflammatory 
conditions is associated with pathophysiological 
processes [47]. In astrocytes, nitric oxide synthase 2 
(NOS2/iNOS) is induced by inflammatory stimuli and the 
nitric oxide (NO) generated by iNOS contributes to 
disease progression in a variety of neurological diseases, 
including AD. Akar and Feinstein (2009) demonstrated 
that SUMOylation regulates iNOS expression in 
astrocytes. Overexpression of the SUMO components 
was able to reduce NOS2 promoter activation, possibly 
involving SUMOylation of the C/EBPβ transcription 
factor [47]. 
A more recent study implicated SUMO in the 
inﬂammatory signaling mediated by Aβ in primary 
astrocytes [48]. This study found that concomitant with 
astrogliosis, Aβ exposure down-regulates SUMO-1 
conjugated proteins, as well as the conjugating enzyme, 
Ubc9, in astrocytes. The JNK inhibition, by the natural 
compound curcumin or a JNK inhibitor, prevented Aβ-
mediated reduction of SUMO-1 conjugation. 
Furthermore, overexpression of constitutively active 
SUMO-1, but not its inactive mutant, abrogated Aβ-
induced GFAP up-regulation and morphological 
reactivity in astrocytes, suggesting an anti-inflammatory 
role for SUMO-1 in the brain. 
Although not much is known about the roles of 
SUMOylation in astrocytes, under pro-inflammatory 
conditions induced by LPS or Aβ, these studies reinforce 
the role of the SUMO pathway in regulating astrocyte 
function and indicate that glial SUMOylation may have 
anti-inflammatory therapeutic benefits. Besides, the 
potential roles of SUMOylation in glia-mediated 
processes in the brain emerge as a new aspect of interest 
in neurodegenerative diseases, such as AD. 
It is therapeutically useful to regulate inflammatory 
processes underlying neurodegenerative diseases, and 
another study has shown that SUMOylation is required for 
suppression of STAT1-dependent inflammatory 
responses by liver X receptors (LXRs) in IFN-γ-
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stimulated brain astrocytes [49]. While not yet directly 
shown, it is probable that such SUMO regulation of 
inﬂammatory signaling also occurs in the microglia. In 
cultured macrophages, peroxisome proliferator-activated 
receptor-gamma (PPAR-γ) and LXRs have been found to 
be SUMOylated, which regulates the transrepression of 
inﬂammatory response genes [50].  
SUMOylation is usually associated with a 
cytoprotective response to cellular stressors. However, we 
note that SUMOylation of certain proteins in astrocytes, 
namely the C-terminal proteolytic fragment of the 
glutamate transporter (EAAT2) has been associated with 
gliotoxicity [51]. EAAT2 is a predominantly astroglial 
glutamate transporter responsible for the majority of 
synaptic glutamate clearance in the mammalian CNS and 
its dysfunction has been linked with many neurological 
disorders. SUMOylation of this astroglial EAAT2 
fragment governs its intracellular compartmentalization 
and accumulation in astrocytes where it triggers 
astrocyte-mediated neurotoxic effects, whereas non-
fragmented EAAT2 resides on the plasma membrane with 
increase in EAAT2-mediated glutamate uptake [52]. The 
same study has also shown evidence that the entire 
EAAT2 protein can be a SUMO target, however, the 
consequences and fate of the SUMOylated transporter 
remain to be elucidated. 
α-Synuclein (α-syn) is the major constituent of Lewy 
bodies and glial cytoplasmic inclusions, which are 
pathological hallmarks of neurodegenerative disorders 
like Parkinson's disease or multiple system atrophy 
(MSA), respectively. In oligodendroglial cells, SUMO-1 
has been implicated in protein aggregation and identified 
as a constituent in inclusion bodies in MSA [53, 54]. 
Although still a relatively underexplored topic, the 
involvement of SUMOylation in glial cells warrant 
additional study and could become a potential therapeutic 
target in brain diseases, including AD as well as other 
neurological diseases. 
 
Conclusions 
 
Since its discovery, SUMOylation is emerging as an 
important post-translational modification for the 
regulation of nuclear cytosolic and membrane proteins in 
the cell. An emerging trend is that this modification does 
not act alone but interplays actively with other 
modifications, such as phosphorylation, acetylation, and 
ubiquitination, to form integrated modification programs 
for coordinated regulation of various proteins in response 
to diverse signaling cues. Overall, the studies strongly 
suggest that there is potentially dysregulation of 
SUMOylation under AD pathology and that such 
dysregulation could involve changes in the SUMO 
enzymes and conjugation profile. There is currently an 
increasing interest on and discovery of neuronal and glial 
SUMO substrates to understand its role in the progression 
and pathology of AD. In addition, components of the 
SUMOylation pathway should now be more deeply 
investigated as not only potential neurodegenerative 
diseases risk factors but also therapeutic targets for drug 
discovery. 
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